Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
AIDS and Behavior
Published in: AIDS and Behavior 5/2014

01-10-2014 | Original Paper

Retention in Care and Adherence to ART are Critical Elements of HIV Care Interventions

Authors: Sebastian M. Stricker, Kathleen A. Fox, Rachel Baggaley, Eyerusalem Negussie, Saskia de Pee, Nils Grede, Martin W. Bloem

Published in: AIDS and Behavior | Special Issue 5/2014

Login to get access

Abstract

Retention in care and adherence to antiretroviral treatment (ART) are critical elements of HIV care interventions and are closely associated with optimal individual and public health outcomes and cost effectiveness. This literature review was conducted to analyse how the roles of clients in HIV care and treatment are discussed, from terminology used to measurement methods to consequences of a wide range of patient-related factors impacting client adherence to ART and retention in care. Unfortunately, data suggests that clients find it hard to follow recommended behaviour. For HIV, the greatest loss to follow-up occurs before starting treatment, though each step of the continuum of care is affected. Measurement approaches can be divided into ‘direct’ and ‘indirect’ methods; in practice, a combination is often considered the best strategy. Inadequate retention and adherence lead to decreased health outcomes (morbidity, mortality, drug resistances, risk of transmission) and cost effectiveness (increased costs and lower productivity).
Footnotes
1
Please note that these numbers relate to total number of tests, as opposed to individuals tested. The number of people testing is likely lower as some may take multiple tests over the course of a year.
 
Literature
1.
Joint United Nations Programme on HIV/AIDS (UNAIDS). Together We Will End AIDS. Geneva: UNAIDS; 2012.
2.
World Health Organization (WHO), United Nations Children’s Fund (UNICEF), Joint United Nations Programme on HIV/AIDS (UNAIDS). Global HIV/AIDS Response: Epidemic Update and Health Sectors Progress Towards Universal Access. Progress Report 2011. Geneva: WHO; 2011.
3.
Vermeire E, Hearnshaw H, Van Royen P, Denekens J. Patient adherence to treatment: three decades of research. A comprehensive review. J Clin Pharm Ther. 2001;25(5):331–42.CrossRef
4.
Haynes RB, McDonald H, Garg AX. Montegue P. Cochrane Database Syst Rev: Interventions for helping patients to follow prescriptions for medications; 2002 (2):CD000011. [NOTE: updated 2005;(4):CD000011.].
5.
DeMaria AN. Adherence, compliance, concordance, or the lack thereof. J Am Coll Cardiol. 2012;59(12):1120–1.PubMedCrossRef
6.
7.
Bell SJ, Airaksinen MS, Lyles A, Chen TF, Aslani P. Concordance is not synonymous with compliance or adherence. Br J Clin Pharmacol. 2007;64(5):710–1.PubMedCrossRefPubMedCentral
8.
9.
10.
Cramer JA, Roy A, Burrell A, et al. Medication compliance and persistence: terminology and definitions. Value Health. 2008;11(1):44–7.PubMedCrossRef
11.
Bissell P, May CR, Noyce PR. From compliance to concordance: barriers to accomplishing a re-framed model of health care interactions. Soc Sci Med. 2004;58(4):851–62.PubMedCrossRef
12.
World Health Organization. Adherence to long-term therapies: evidence for action. Geneva: WHO; 2003.
13.
Lamb MR, El-Sadr WM, Geng E, Nash D. Association of adherence support and outreach services with total attrition, loss to follow-up, and death among ART patients in sub-Saharan Africa. PLoS One. 2012;7(6):e38443.PubMedCrossRefPubMedCentral
14.
Chi BH, Cantrell RA, Mwango A, et al. An empirical approach to defining loss to follow-up among patients enrolled in antiretroviral treatment programs. Am J Epidemiol. 2010;171(8):924–31.PubMedCrossRefPubMedCentral
15.
Chi BH, Yiannoutsos CT, Westfall AO, et al. Universal definition of loss to follow-up in HIV treatment programs: a statistical analysis of 111 facilities in Africa, Asia, and Latin America. PLoS Med. 2011;8(10):e1001111.PubMedCrossRefPubMedCentral
16.
Fairman K, Motheral B. Evaluating medication adherence: which measure is right for your program? J Manage Care Pharm. 2000;6:499–504.
17.
Berg KM, Arnsten JH. Practical and conceptual challenges in measuring antiretroviral adherence. J Acquir Immune Defic Syndr. 2006;43(Suppl 1):S79–87.PubMedCrossRefPubMedCentral
18.
Miller LG, Hays RD. Measuring adherence to antiretroviral medications in clinical trials. HIV Clin Trials. 2000;1(1):36–46.PubMedCrossRef
19.
Mannheimer S, Friedland G, Matts J, Child C, Chesney M. The consistency of adherence to antiretroviral therapy predicts biologic outcomes for human immunodeficiency virus-infected persons in clinical trials. Clin Infect Dis. 2002;34(8):1115–21.PubMedCrossRef
20.
21.
Holzemer WL, Corless IB, Nokes KM, et al. Predictors of self-reported adherence in persons living with HIV disease. AIDS Patient Care STDS. 1999;13(3):185–97.PubMedCrossRef
22.
Stone VE, Hogan JW, Schuman P, et al. Antiretroviral regimen complexity, self-reported adherence, and HIV patients’ understanding of their regimens: survey of women in the her study. J Acquir Immune Defic Syndr. 2001;28(2):124–31.PubMedCrossRef
23.
Jackevicius CA, Mamdani M, Tu JV. Adherence with statin therapy in elderly patients with and without acute coronary syndromes. JAMA. 2002;288(4):462–7.PubMedCrossRef
24.
Cramer J, Rosenheck R, Kirk G, Krol W, Krystal J, VA Naltrexone Study Group 425. Medication compliance feedback and monitoring in a clinical trial: predictors and outcomes. Value Health. 2003;6(5):566–73.PubMedCrossRef
25.
Mills EJ, Nachega JB, Buchan I, et al. Adherence to antiretroviral therapy in sub-Saharan Africa and North America: a meta-analysis. JAMA. 2006;296(6):679–90.PubMedCrossRef
26.
Ortego C, Huedo-Medina TB, Llorca J, et al. Adherence to highly active antiretroviral therapy (HAART): a meta-analysis. AIDS Behav. 2011;15(7):1381–96.PubMedCrossRef
27.
DiMatteo MR. Variations in patients’ adherence to medical recommendations: a quantitative review of 50 years of research. Med Care. 2004;42(3):200–9.PubMedCrossRef
28.
Coenen T, Lundgren J, Lazarus JV, Matic S. Optimal HIV testing and earlier care: the way forward in Europe. HIV Med. 2008;9(Suppl 2):1–5.PubMedCrossRef
29.
US Centers for Disease Control and Prevention (CDC). HIV surveillance—United States, 1981–2008. Morb Mortal Wkly Rep. 2011;60(21):689–93.
30.
Girardi E, Sabin CA, Monforte AD. Late diagnosis of HIV infection: epidemiological features, consequences and strategies to encourage earlier testing. J Acquir Immune Defic Syndr. 2007;46(Suppl 1):S3–8.PubMedCrossRef
31.
32.
Gardner EM, McLees MP, Steiner JF, del Rio C, Burman WJ. The spectrum of engagement in HIV care and its relevance to test-and-treat strategies for prevention of HIV infection. Clin Infect Dis. 2011;52(6):793–800.PubMedCrossRefPubMedCentral
33.
Ingle SM, May M, Uebel K, et al. Outcomes in patients waiting for antiretroviral treatment in the Free State Province, South Africa: prospective linkage study. AIDS. 2010;24(17):2717–25.PubMedCrossRefPubMedCentral
34.
Lawn SD, Myer L, Harling G, Orrell C, Bekker LG, Wood R. Determinants of mortality and nondeath losses from an antiretroviral treatment service in South Africa: implications for program evaluation. Clin Infect Dis. 2006;43(6):770–6.PubMedCrossRef
35.
Thai S, Koole O, Un P, et al. Five-year experience with scaling-up access to antiretroviral treatment in an HIV care programme in Cambodia. Trop Med Int Health. 2009;14(9):1048–58.PubMedCrossRef
36.
Fox MP, Rosen S. Patient retention in antiretroviral therapy programs up to three years on treatment in sub-Saharan Africa, 2007–2009: systematic review. Trop Med Int Health. 2010;15(Suppl 1):1–15.PubMedCrossRefPubMedCentral
37.
Urquhart J. Defining the margins for errors in patient compliance with prescribed drug regimens. Pharmacoepidemiol Drug Saf. 2000;9(7):565–8.PubMedCrossRef
38.
Paes AH, Bakker A, Soe-Agnie CJ. Measurement of patient compliance. Pharm World Sci. 1998;20(2):73–7.PubMedCrossRef
39.
Farmer KC. Methods for measuring and monitoring medication regimen adherence in clinical trials and clinical practice. Clin Ther. 1999;21(6):1074–90.PubMedCrossRef
40.
Vitolins MZ, Rand CS, Rapp SR, Ribisl PM, Sevick MA. Measuring adherence to behavioral and medical interventions. Control Clin Trials. 2000;21(Suppl 5):S188–94.CrossRef
41.
Nunnally JC, Berstein I. Psychometric theory. 3rd ed. New York: McGraw-Hill; 1994.
42.
McMahon JH, Jordan MR, Kelley K, et al. Pharmacy adherence measures to assess adherence to antiretroviral therapy: review of the literature and implications for treatment monitoring. Clin Infect Dis. 2011;52(4):493–506.PubMedCrossRefPubMedCentral
43.
Chalker JC, Andualem T, Gitau LN, et al. Measuring adherence to antiretroviral treatment in resource-poor settings: the feasibility of collecting routine data for key indicators. BMC Health Serv Res. 2010;19(10):43.CrossRef
44.
Ross-Degnan D, Pierre-Jacques M, Zhang F, et al. Measuring adherence to antiretroviral treatment in resource-poor settings: the clinical validity of key indicators. BMC Health Serv Res. 2010;19(10):42.CrossRef
45.
Steel G, Nwokike J, Joshi MP. Development of a Multi-Method Tool to Measure ART Adherence in Resource-Constrained Settings: The South Africa Experience. Submitted to the USAID by RPM plus. Arlington, Va: Management Sciences for Health; 2007.
46.
Herbst AJ, Cooke GS, Bärnighausen T, KanyKany A, Tanser F, Newell ML. Adult mortality and antiretroviral treatment roll-out in rural KwaZulu-Natal, South Africa. Bull World Health Organ. 2009;87(10):754–62.PubMedCrossRefPubMedCentral
47.
Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N Engl J Med. 1997;337(11):725–33.PubMedCrossRef
48.
Michaels SH, Clark R, Kissinger P. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med. 1998;339(6):405–6.PubMedCrossRef
49.
Chan KC, Wong KH, Lee SS. Universal decline in mortality in patients with advanced HIV-1 disease in various demographic subpopulations after the introduction of HAART in Hong Kong, from 1993 to 2002. HIV Med. 2006;7(3):186–92.PubMedCrossRef
50.
World Health Organization (WHO). WHO Global Strategy for Containment of Antimicrobial Resistance. Geneva: WHO; 2001.
51.
Phillips A, Pezzotti P. CASCADE Collaboration. Short-term risk of AIDS according to current CD4 cell count and viral load in antiretroviral drug-naive individuals and those treated in the monotherapy era. AIDS. 2004;18(1):51–8.PubMedCrossRef
52.
Sabin CA, Smith CJ, Gumley H, et al. Late presenters in the era of highly active antiretroviral therapy: uptake of and responses to antiretroviral therapy. AIDS. 2004;18(16):2145–51.PubMedCrossRef
53.
Hocking JS, Rodger AJ, Rhodes DG, Crofts N. Late presentation of HIV infection associated with prolonged survival following AIDS diagnosis—characteristics of individuals. Int J STD AIDS. 2000;11(8):503–8.PubMedCrossRef
54.
Bangsberg DR, Perry S, Charlebois ED, et al. Non-adherence to highly active antiretroviral therapy predicts progression to AIDS. AIDS. 2001;15(9):1181–3.PubMedCrossRef
55.
de Olalla PG, Knobel H, Carmona A, Guelar A, López-Colomés JL, Caylà JA. Impact of adherence and highly active antiretroviral therapy on survival in HIV-infected patients. J Acquir Immune Defic Syndr. 2002;30(1):105–10.CrossRef
56.
Hoggs RS, Heath K, Bangsberg D, et al. Intermittent use of triple-combination therapy is predictive of mortality at baseline and after 1 year of follow-up. AIDS. 2002;16(7):1051–8.CrossRef
57.
Grossberg R, Zhang Y, Gross R. A time-to-prescription-refill measure of antiretroviral adherence predicted changes in viral load in HIV. J Clin Epidemiol. 2004;57(10):1107–10.PubMedCrossRef
58.
Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med. 2000;133(1):21–30.PubMedCrossRef
59.
Nachega JB, Hislop M, Dowdy DW, et al. Adherence to highly active antiretroviral therapy assessed by pharmacy claims predicts survival in HIV-infected South African adults. J Acquir Immune Defic Syndr. 2006;43(1):78–84.PubMedCrossRef
60.
Giordano TP, Gifford AL, White AC Jr, et al. Retention in care: a challenge to survival with HIV infection. Clin Infect Dis. 2007;44(11):1493–9.PubMedCrossRef
61.
Bangsberg DR, Moss AR, Deeks SG. Paradoxes of adherence and drug resistance to HIV antiretroviral therapy. J Antimicrob Chemother. 2004;53(5):696–9.PubMedCrossRef
62.
Green DA. There are no paradoxes of adherence and drug resistance to HIV antiretroviral therapy. J Antimicrob Chemother. 2004;54(3):694.PubMedCrossRef
63.
Bangsberg DR, Kroetz DL, Deeks SG. Adherence-resistance relationships to combination HIV antiretroviral therapy. Curr HIV/AIDS Rep. 2007;4(2):65–72.PubMedCrossRef
64.
Gardner EM, Burman WJ, Steiner JF, Anderson PL, Bangsberg DR. Antiretroviral medication adherence and the development of class-specific antiretroviral resistance. AIDS. 2009;23(9):1035–46.PubMedCrossRefPubMedCentral
65.
Gardner EM, Sharma S, Peng G, et al. Differential adherence to combination antiretroviral therapy is associated with virological failure with resistance. AIDS. 2008;22(1):75–82.PubMedCrossRefPubMedCentral
66.
World Health Organization (WHO). Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach. 2010 Revision. Geneva: WHO; 2010. p. 2010.
67.
Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. Washington, DC: US Department of Health and Human Services; 2012.
68.
69.
World Health Organization (WHO). WHO HIV Drug Resistance Report 2012. Geneva: WHO; 2012.
70.
71.
Attia S, Egger M, Müller M, Zwahlen M, Low N. Sexual transmission of HIV according to viral load and antiretroviral therapy: systematic review and meta-analysis. AIDS. 2009;23(11):1397–404.PubMedCrossRef
72.
Donnell D, Baeten JM, Kiarie J, et al. Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysis. Lancet. 2010;375(9731):2092–8.PubMedCrossRefPubMedCentral
73.
Nachega JB, Leisegang R, Bishai D, et al. Association of antiretroviral therapy adherence and health care cost. Ann Intern Med. 2010;152(1):18–25.PubMedCrossRef
74.
Knobel H, Carmona A, Guelar A, Gonzolez A, Hernecki J, Diez A. Adherence in patients treated with HAART: influence in hospital admissions. Durban: International AIDS Conference; 2000 [abstract MoPeD2556].
75.
Long L, Fox M, Sanne I, Rosen S. The high cost of second-line antiretroviral therapy for HIV/AIDS in South Africa. AIDS. 2010;24(6):915–9.PubMedCrossRef
76.
World Health Organization (WHO), Joint United Nations Programme on HIV/AIDS (UNAIDS). The Treatment 2.0 Framework for Action: Catalysing the Next Phase of Treatment, Care and Support. Geneva: WHO; 2011.
77.
Coleman CI, Roberts MS, Sobieraj DM, Lee S, Alam T, Kaur R. Effect of dosing frequency on chronic cardiovascular disease medication adherence. Curr Med Res Opin. 2012;28(5):669–80.PubMedCrossRef
78.
Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther. 2001;23(8):1296–310.PubMedCrossRef
79.
Reginster JY, Rabenda V, Neuprez A. Adherence, patient preference and dosing frequency: understanding the relationship. Bone. 2006;4(Suppl 1):S2–6.CrossRef
80.
Ma A, Chen DM, Chau FM, Saberi P. Improving adherence and clinical outcomes through an HIV pharmacist’s interventions. AIDS Care. 2010;22(19):1189–94.PubMedCrossRef
81.
Kigozi IM, Dobkin LM, Martin JN, et al. Late-disease stage at presentation to an HIV clinic in the era of free antiretroviral therapy in sub-Saharan Africa. J Acquir Immune Defic Syndr. 2009;52(2):280–9.PubMedCrossRefPubMedCentral
82.
Kitahata MM, Gange SJ, Abraham AG, et al. Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med. 2009;360(18):1815–26.PubMedCrossRefPubMedCentral
83.
Jani AV, Sitoe AE, Alfai ER, et al. Effect of point-of-care CD4 cell count tests on retention of patients and rates of antiretroviral therapy initiation in primary health clinics: an observational cohort study. Lancet. 2011;378(9802):1572–9.PubMedCrossRef
84.
Joint United Nations Programme on HIV/AIDS (UNAIDS). Breaking News Supplement: Meeting the Investment Challenge. Geneva: UNAIDS; 2012.
85.
Torpey K, Kabaso M, Kasonde P, et al. Increasing the uptake of prevention of mother-to-child transmission of HIV services in a resource-limited setting. BMC Health Serv Res. 2010;10:29.PubMedCrossRefPubMedCentral
86.
Killam WP, Tambatamba BC, Chintu N, et al. Antiretroviral therapy in antenatal care to increase treatment initiation in HIV-infected pregnant women: a stepped-wedge evaluation. AIDS. 2010;24(1):85–91.PubMedCrossRef
87.
Louwagie G, Girdler-Brown B, Odendaal R, Rossouw T, Johnson S, Van der Walt M. Missed opportunities for accessing HIV care among Tshwane tuberculosis patients under different models of care. Int J Tuberc Lung Dis. 2012;16(8):1052–8.PubMedCrossRef
88.
Tuller DM, Bangsberg DR, Senkungu J, Ware NC, Emenyonu N, Weiser SD. Transportation costs impede sustained adherence and access to HAART in a clinic population in southwestern Uganda: a qualitative study. AIDS Behav. 2010;14(4):778–84.PubMedCrossRefPubMedCentral
89.
Hardon AP, Akurut D, Comoro C, et al. Hunger, waiting time and transport costs: time to confront challenges to ART adherence in Africa. AIDS Care. 2007;19(5):658–65.PubMedCrossRef
90.
Ware NC, Idoko J, Kaaya S, et al. Explaining adherence success in sub-Saharan Africa: an ethnographic study. PLoS Med. 2009;6(1):e1000011.CrossRefPubMedCentral
91.
Wouters E, Van Damme W, van Rensburg D, Meulemans H. Impact of baseline health and community support on antiretroviral treatment outcomes in HIV patients in South Africa. AIDS. 2008;22(18):2545–8.PubMedCrossRef
92.
Decroo T, Telfer B, Biot M, et al. Distribution of antiretroviral treatment through self-forming groups of patients in Tete province, Mozambique. J Acquir Immune Defic Syndr. 2011;56(2):e39–44.PubMedCrossRef
93.
United Nations General Assembly. Political Declaration on HIV and AIDS: Intensifying Our Efforts to Eliminate HIV and AIDS. New York: United Nations General Assembly; 2011.
94.
Joint United Nations Programme on HIV/AIDS (UNAIDS). Getting to Zero: 2011-2015 Strategy. Geneva: UNAIDS; 2010.
Metadata
Title
Retention in Care and Adherence to ART are Critical Elements of HIV Care Interventions
Authors
Sebastian M. Stricker
Kathleen A. Fox
Rachel Baggaley
Eyerusalem Negussie
Saskia de Pee
Nils Grede
Martin W. Bloem
Publication date
01-10-2014
Publisher
Springer US
Published in
AIDS and Behavior / Issue Special Issue 5/2014
Print ISSN: 1090-7165
Electronic ISSN: 1573-3254
DOI
https://doi.org/10.1007/s10461-013-0598-6

Other articles of this Special Issue 5/2014

AIDS and Behavior 5/2014 Go to the issue

Original Paper

The Enabling Effect of Food Assistance in Improving Adherence and/or Treatment Completion for Antiretroviral Therapy and Tuberculosis Treatment: A Literature Review

Original Paper

Tailored Nutrition Education and Food Assistance Improve Adherence to HIV Antiretroviral Therapy: Evidence from Honduras

Original Paper

Is There a Need to Mitigate the Social and Financial Consequences of Tuberculosis at the Individual and Household Level?

Original Paper

Adherence to HIV and TB Care and Treatment, the Role of Food Security and Nutrition

Original Paper

Food Security in the Context of HIV: Towards Harmonized Definitions and Indicators

Original Paper

A Review of the Role of Food Insecurity in Adherence to Care and Treatment Among Adult and Pediatric Populations Living with HIV and AIDS
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits